Nurix Therapeutics
NRIX
170 hedge funds and large institutions have $1.01B invested in Nurix Therapeutics in 2025 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 66 increasing their positions, 52 reducing their positions, and 32 closing their positions.
709% more call options, than puts
Call options by funds: $777K | Put options by funds: $96K
27% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 52
3% less funds holding
Funds holding: 175 → 170 (-5)
3.01% less ownership
Funds ownership: 114.49% → 111.48% (-3%)
13% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 32
34% less capital invested
Capital invested by funds: $1.53B → $1.01B (-$523M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$41.8M |
| 2 |
CC
Commodore Capital
New York
|
+$16.4M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$13.4M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$10.7M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.9M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.43M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.25M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.65M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$6.01M |
NRIX Hedge Fund Activity: Q1 2025 in Review
170 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2025, worth a combined $1.01B — down 34% from $1.53B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of NRIX and 28 opened new positions — a net loss of 4 holders — while 52 trimmed existing stakes and 66 added.
The largest buyer was Deep Track Capital, adding an estimated $41.8M. The largest seller was Point72 Asset Management, cutting an estimated $10.9M.
- 170 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2025, down from 175 in Q4 2024.
- Funds reported $1.01B of Nurix Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 28 funds opened new Nurix Therapeutics positions in Q1 2025 and 32 closed out, a net change of -4 holders.
- The largest Nurix Therapeutics buyer in Q1 2025 was Deep Track Capital, an estimated $41.8M added.
- The largest Nurix Therapeutics seller in Q1 2025 was Point72 Asset Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2025.